Header Logo

MILIND JAVLE

TitleProfessor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525. PMID: 38297981; PMCID: PMC10994248.
      Citations:    Fields:    
    2. Nelson BE, Roszik J, Ahmed J, Barretto CMN, Nardo M, Campbell E, Johnson AM, Piha-Paul SA, Oliva ICG, Weathers SP, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer. 2024 03 26; 23(1):64. PMID: 38532456; PMCID: PMC10964523.
      Citations:    Fields:    Translation:Humans
    3. Makawita S, Lee S, Kong E, Kwong LN, Abouelfetouh Z, Danner De Armas A, Xiao L, Murugesan K, Danziger N, Pavlick D, Korkut A, Ross JS, Javle M. Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 Mar; 8:e2300544. PMID: 38547421; PMCID: PMC10994443.
      Citations:    Fields:    
    4. DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024 Feb 15. PMID: 38358339.
      Citations:    Fields:    
    5. Ngoi NYL, Tang TY, Gaspar CF, Pavlick DC, Buchold GM, Scholefield EL, Parimi V, Huang RSP, Janovitz T, Danziger N, Levy MA, Pant S, De Armas AD, Kumpula D, Ross JS, Javle M, Ahnert JR. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. Oncologist. 2024 Feb 08. PMID: 38330461.
      Citations:    Fields:    
    6. Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol. 2024 Feb; 7(1):7-17. PMID: 38327755; PMCID: PMC10846638.
      Citations:    
    7. Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2). PMID: 38309721; PMCID: PMC10840042.
      Citations:    Fields:    Translation:HumansCells
    8. Jain AJ, Lendoire M, Boyev A, Newhook TE, Tzeng CD, Tran Cao HS, Coronel E, Lee SS, Hu ZI, Javle M, Lee JH, Vauthey JN, Chun YS. Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress? Ann Surg Oncol. 2024 May; 31(5):3062-3068. PMID: 38282027.
      Citations: 1     Fields:    
    9. Zhu Y, Zhang D, Shukla P, Jung YH, Malgulwar PB, Chagani S, Colic M, Benjamin S, Copland Iii JA, Tan L, Lorenzi PL, Javle M, Huse JT, Roszik J, Hart T, Kwong LN, Zhu Y, Zhang D, Shukla P, Jung YH, Malgulwar PB, Chagani S, Colic M, Benjamin S, Copland JA, Tan L, Lorenzi PL, Javle M, Huse JT, Roszik J, Hart T, Kwong LN. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight. 2024 Jan 23; 9(2). PMID: 38060314; PMCID: PMC10906219.
      Citations:    Fields:    Translation:HumansCells
    10. Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M, Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res. 2023 12 01; 29(23):4853-4862. PMID: 37773629.
      Citations: 2     Fields:    Translation:Humans
    11. DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F, DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334. PMID: 37972659.
      Citations:    Fields:    Translation:HumansAnimals
    12. Javle M, King G, Spencer K, Borad MJ. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. Oncologist. 2023 Nov 02; 28(11):928-943. PMID: 37390492; PMCID: PMC10628593.
      Citations: 1     Fields:    Translation:Humans
    13. Hatia RI, Eluri M, Hawk ET, Shalaby A, Karatas E, Shalaby A, Abdelhakeem A, Abdel-Wahab R, Chang P, Rashid A, Jalal PK, Amos CI, Han Y, Armaghany T, Shroff RT, Li D, Javle M, Hassan MM. Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347. PMID: 37540502.
      Citations: 1     Fields:    Translation:Humans
    14. Koay EJ, Javle M, Belknap M, Derasari S, Roach M, Ludmir EB. What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma? Cancer J. 2023 Sep-Oct 01; 29(5):272-278. PMID: 37796645.
      Citations:    Fields:    Translation:Humans
    15. Pappas L, Baiev I, Reyes S, Bocobo AG, Jain A, Spencer K, Le TM, Rahma OE, Maurer J, Stanton J, Zhang K, De Armas AD, Deleon TT, Roth M, Peters MLB, Zhu AX, Boyhen K, VanCott C, Patel T, Roberts LR, Lindsey S, Horick N, Lennerz JK, Iafrate AJ, Goff LW, Mody K, Borad MJ, Shroff RT, Javle MM, Kelley RK, Goyal L. The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma. JCO Precis Oncol. 2023 08; 7:e2200594. PMID: 37561981; PMCID: PMC10581631.
      Citations:    Fields:    Translation:Humans
    16. Pappas L, Baiev I, Maurer J, Jain A, De Armas AD, Reyes S, Rahma OE, Stanton J, DeLeon TT, Peters MLB, Iafrate AJ, Boyhen K, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Javle MM, Spencer K, Bocobo AG, Zhang K, Le TM, Roth M, Zhu AX, Lennerz JK, VanCott C, Roberts LR, Kelley RK, Goyal L. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. J Natl Cancer Inst. 2023 07 06; 115(7):870-880. PMID: 37040087; PMCID: PMC10323903.
      Citations:    Fields:    Translation:Humans
    17. Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023 Oct; 30(11):6558-6566. PMID: 37368098; PMCID: PMC10883654.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    18. Ngo-Huang AT, Parker NH, Xiao L, Schadler KL, Petzel MQB, Prakash LR, Kim MP, Tzeng CD, Lee JE, Ikoma N, Wolff RA, Javle MM, Koay EJ, Pant SD, Folloder JP, Wang X, Cotto AM, Ju YR, Garg N, Wang H, Bruera ED, Basen-Engquist KM, Katz MHG. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. Ann Surg. 2023 07 01; 278(1):22-30. PMID: 37026453; PMCID: PMC10330108.
      Citations: 2     Fields:    Translation:Humans
    19. Dodoo GN, De B, Lee SS, Abi Jaoude J, Vauthey JN, Tzeng CD, Tran Cao HS, Katlowitz KA, Mandel JJ, Beckham TH, Minsky BD, Smith GL, Holliday EB, Koong AC, Das P, Taniguchi CM, Javle M, Koay EJ, Ludmir EB. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist. 2023 04 06; 28(4):327-332. PMID: 36715178; PMCID: PMC10078902.
      Citations:    Fields:    Translation:Humans
    20. Yoo C, Raoul JL, Kim JW, Ueno M, Lee CK, Hijioka S, Furuse J, Sato M, Bridgewater J, Oh DY, Javle MM, Verdaguer Mata H, de Braud F, Trojan J, Cubillo A, Azad N, Vugmeyster Y, Machl A, Bajars M, Borad MJ. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology. 2023 09 01; 78(3):758-770. PMID: 36999533; PMCID: PMC10442127.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    21. De B, Upadhyay R, Liao K, Kumala T, Shi C, Dodoo G, Abi Jaoude J, Corrigan KL, Manzar GS, Marqueen KE, Bernard V, Lee SS, Raghav KPS, Vauthey JN, Tzeng CD, Tran Cao HS, Lee G, Wo JY, Hong TS, Crane CH, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer. 2023 Aug; 12(3):198-208. PMID: 37593365; PMCID: PMC10427952.
      Citations:    
    22. Janku F, Javle MM, Sen S, Pant S, Bramwell LG, Subbiah V, Way T, Wages DS, Wheeler CA, Suzuki T, Saeki K, Subach RA, Madden T, Maier G, Johansen MJ, Cheung K, Falchook GS. A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer. 2023 05 15; 129(10):1537-1546. PMID: 36882377.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    23. Abboud K, Umoru G, Esmail A, Abudayyeh A, Murakami N, Al-Shamsi HO, Javle M, Saharia A, Connor AA, Kodali S, Ghobrial RM, Abdelrahim M. Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers (Basel). 2023 Feb 23; 15(5). PMID: 36900226; PMCID: PMC10000896.
      Citations:    
    24. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19. PMID: 36801912; PMCID: PMC9938883.
      Citations:    
    25. Tennison JM, Asher A, Hui D, Javle M, Bassett RL, Bruera E. Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer. Oncologist. 2023 02 08; 28(2):180-186. PMID: 36367387; PMCID: PMC9907049.
      Citations:    Fields:    Translation:Humans
    26. Ayabe RI, Paez-Arango N, Estrella JS, Newhook TE, Tzeng CD, Chun YS, Lee S, Javle M, Vauthey JN, Tran Cao HS. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes? HPB (Oxford). 2023 04; 25(4):472-480. PMID: 36781357.
      Citations: 1     Fields:    Translation:Humans
    27. Connor AA, Kodali S, Abdelrahim M, Javle MM, Brombosz EW, Ghobrial RM. Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers. Front Oncol. 2022; 12:996710. PMID: 36479082; PMCID: PMC9719919.
      Citations:    
    28. Roa JC, Garc?a P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Publisher Correction: Gallbladder cancer. Nat Rev Dis Primers. 2022 Nov 18; 8(1):75. PMID: 36400795.
      Citations: 1     Fields:    
    29. Roa JC, Garc?a P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022 10 27; 8(1):69. PMID: 36302789.
      Citations: 15     Fields:    Translation:Humans
    30. Schalck A, Sakellariou-Thompson D, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C, Forget MA. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discov. 2022 10 05; 12(10):2330-2349. PMID: 35849783; PMCID: PMC9547957.
      Citations:    Fields:    
    31. Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, Teschemaker A, Chopra I, Janjan N, Parasuraman S, Bekaii-Saab TS. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist. 2022 Oct 01; 27(10):874-883. PMID: 35972334; PMCID: PMC9526482.
      Citations:    
    32. Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Uson Junior PLS, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol. 2022 Dec; 33(12):1269-1283. PMID: 36089135.
      Citations:    
    33. Hester CA, Perri G, Prakash LR, Maxwell JE, Ikoma N, Kim MP, Tzeng CD, Smaglo B, Wolff R, Javle M, Overman MJ, Lee JE, Katz MHG. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. J Natl Compr Canc Netw. 2022 08; 20(8):887-897.e3. PMID: 35948035.
      Citations:    
    34. Koay EJ, Zaid M, Aliru M, Bagereka P, Van Wieren A, Rodriguez MJ, Jacobson G, Wolff RA, Overman M, Varadhachary G, Pant S, Wang H, Tzeng CW, Ikoma N, Kim M, Lee JE, Katz MH, Tamm E, Bhosale P, Taniguchi CM, Holliday EB, Smith GL, Ludmir EB, Minsky BD, Crane CH, Koong AC, Das P, Wang X, Javle M, Krishnan S. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453. PMID: 35863672.
      Citations:    Fields:    
    35. Lee S, Shroff RT, Makawita S, Xiao L, Danner De Armas A, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff RA, Javle M. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clin Cancer Res. 2022 06 01; 28(11):2229-2236. PMID: 35312753.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    36. De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 2022 07 01; 128(13):2529-2539. PMID: 35417569; PMCID: PMC9177808.
      Citations:    Fields:    Translation:Humans
    37. Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey JN, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2022 Apr 09; 14(8). PMID: 35454808; PMCID: PMC9032898.
      Citations:    
    38. Silverman IM, Li M, Murugesan K, Krook MA, Javle MM, Kelley RK, Borad MJ, Roychowdhury S, Meng W, Yilmazel B, Milbury C, Shewale S, Burn TC, Albacker LA, Feliz L. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. J Mol Diagn. 2022 04; 24(4):351-364. PMID: 35176488.
      Citations:    Fields:    Translation:Humans
    39. DiPeri TP, Demirhan M, Karp DD, Fu S, Hong DS, Subbiah V, Lim J, Ballester LY, Tayar JH, Suarez-Almazor ME, Javle M, Meric-Bernstam F. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol. 2022 Feb; 5(1):26-30. PMID: 35663835; PMCID: PMC9138421.
      Citations:    
    40. Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, Gouda MA, Raina A, Madwani K, Holley VR, Call SG, Dustin DJ, Lanman RB, Meric-Bernstam F, Raymond VM, Kwong LN, Janku F. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol. 2022 02; 6:e2100197. PMID: 35171660; PMCID: PMC8865526.
      Citations:    Fields:    Translation:Humans
    41. Javle M, Bustamante J, Salcedo M, Vinaixa C, Trapero-Marug?n M, Line PD. Evaluation and Management of Liver Transplant Candidates With Prior Nonhepatic Cancer: Guidelines From the ILTS/SETH Consensus Conference. Transplantation. 2022 01 01; 106(1):e3-e11. PMID: 34905758.
      Citations:    Fields:    Translation:Humans
    42. Panettieri E, Maki H, Kim BJ, Kang HC, Cox V, Vega EA, Mizuno T, Pant S, Javle M, Vauthey JN, Kawaguchi Y. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol. 2022 Mar; 40:101696. PMID: 34995974; PMCID: PMC8863406.
      Citations:    Fields:    Translation:Humans
    43. McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, Hobeika MJ, Lunsford KE, Victor DW, Shetty A, McFadden RS, Abdelrahim M, Kaseb A, Divatia M, Yu N, Nolte Fong J, Moore LW, Nguyen DT, Graviss EA, Gaber AO, Vauthey JN, Ghobrial RM. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. 2022 03; 22(3):823-832. PMID: 34856069.
      Citations: 4     Fields:    Translation:Humans
    44. Javle MM, Oh DY, Ikeda M, Yong WP, Hsu K, Lindmark B, McIntyre N, Firth C. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp). ESMO Open. 2022 02; 7(1):100314. PMID: 34922298; PMCID: PMC8685988.
      Citations:    Translation:HumansCTClinical Trials
    45. Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308. PMID: 34510503; PMCID: PMC8766948.
      Citations: 3     Fields:    Translation:HumansCells
    46. De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med. 2021 Dec 01; 11(12). PMID: 34945742; PMCID: PMC8703854.
      Citations: 1     
    47. Gupta P, Dutta U, Rana P, Singhal M, Gulati A, Kalra N, Soundararajan R, Kalage D, Chhabra M, Sharma V, Gupta V, Yadav TD, Kaman L, Irrinki S, Singh H, Sakaray Y, Das CK, Saikia U, Nada R, Srinivasan R, Sandhu MS, Sharma R, Shetty N, Eapen A, Kaur H, Kambadakone A, de Haas R, Kapoor VK, Barreto SG, Sharma AK, Patel A, Garg P, Pal SK, Goel M, Patkar S, Behari A, Agarwal AK, Sirohi B, Javle M, Garcea G, Nervi F, Adsay V, Roa JC, Han HS. Gallbladder reporting and data system (GB-RADS) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus. Abdom Radiol (NY). 2022 02; 47(2):554-565. PMID: 34851429.
      Citations: 1     Fields:    Translation:Humans
    48. Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677. PMID: 34554208; PMCID: PMC8461552.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    49. Martin NA, Tepper JE, Giri VN, Stinchcombe TE, Cheng HH, Javle MM, Konnick EQ. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precis Oncol. 2021; 5. PMID: 34651094; PMCID: PMC8509918.
      Citations: 1     Fields:    Translation:Humans
    50. Rogers JE, Mizrahi JD, Nogueras Gonzalez GM, Surana R, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Raghav K, Pant S. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol. 2021 Oct; 12(5):2268-2274. PMID: 34790391; PMCID: PMC8576228.
      Citations:    
    51. Meric-Bernstam F, Bahleda R, Hierro C, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L, Sanson M. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discov. 2022 02; 12(2):402-415. PMID: 34551969; PMCID: PMC9762334.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    52. Murugesan K, Sharaf R, Montesion M, Moore JA, Pao J, Pavlick DC, Frampton GM, Upadhyay VA, Alexander BM, Miller VA, Javle MM, Bekaii Saab TS, Albacker LA, Ross JS, Ali SM. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol. 2021 08; 5. PMID: 34476330; PMCID: PMC8384404.
      Citations:    Fields:    Translation:Humans
    53. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK, Waldschmidt DT, Bitzer M. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815. PMID: 34358484.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    54. Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 09; 22(9):1290-1300. PMID: 34339623.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    55. King G, Javle M. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Curr Oncol Rep. 2021 07 16; 23(9):108. PMID: 34269915.
      Citations:    Fields:    Translation:HumansCells
    56. Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050. PMID: 34250759; PMCID: PMC8335807.
      Citations: 4     Fields:    Translation:Humans
    57. Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers (Basel). 2021 Jun 13; 13(12). PMID: 34199304; PMCID: PMC8231807.
      Citations: 4     
    58. Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing A. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52. PMID: 35663531; PMCID: PMC9153261.
      Citations: 3     
    59. Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, Boursi B, Uruba S, Margalit O, Wolff RA, Golan T. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol. 2021 May 01; 7(5):693-699. PMID: 33662100; PMCID: PMC7934074.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    60. Lee SH, Simoneau EB, Karpinets T, Futreal PA, Zhang J, Javle M, Zhang J, Vauthey JN, Lee JS, Estrella JS, Chun YS. Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations. Carcinogenesis. 2021 04 17; 42(3):436-441. PMID: 33200197; PMCID: PMC8052956.
      Citations: 4     Fields:    Translation:Humans
    61. Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813. PMID: 31274655; PMCID: PMC7703852.
      Citations: 13     Fields:    Translation:Humans
    62. DiPeri TP, Javle MM, Meric-Bernstam F. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol. 2021 May; 15(5):471-474. PMID: 33641586; PMCID: PMC8172427.
      Citations: 2     Fields:    Translation:Humans
    63. Mason MC, Massarweh NN, Tzeng CD, Chiang YJ, Chun YS, Aloia TA, Javle M, Vauthey JN, Tran Cao HS. Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Ann Surg Oncol. 2021 Oct; 28(11):6725-6735. PMID: 33586068.
      Citations: 4     Fields:    Translation:Humans
    64. Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. J Pain Symptom Manage. 2021 08; 62(2):223-232.e1. PMID: 33388382.
      Citations:    Fields:    Translation:Humans
    65. Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 12 16; 10(1):22087. PMID: 33328484; PMCID: PMC7745036.
      Citations: 9     Fields:    Translation:HumansCells
    66. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Liz?e G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun. 2020 10 21; 11(1):5332. PMID: 33087697; PMCID: PMC7577998.
      Citations: 5     Fields:    Translation:HumansCells
    67. Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Bauer TM, Javle M, Pant S, Bendell J, Hung A, Ratti N, VanVlasselaer P, Verma R, Leveque J, Rao S, Oft M, Naing A. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192. PMID: 32910338; PMCID: PMC8944136.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    68. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839. PMID: 32667641; PMCID: PMC7364337.
      Citations: 29     Fields:    Translation:Humans
    69. Subbiah V, Lassen U, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA, ?lez E, Italiano A. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 09; 21(9):1234-1243. PMID: 32818466.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    70. Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Goyal L, Cohn A, Lamarca A, Oh DY, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M, Borbath I, Macarulla T. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Oct; 16(30):2375-2384. PMID: 32580579.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    71. Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415. PMID: 32519420; PMCID: PMC7402810.
      Citations: 2     Fields:    Translation:Humans
    72. Sapisochin G, Javle M, Ohtsuka M, Ghobrial M, Hibi T, Kwan NM, Heimbach J, Lerut J. Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020 06; 104(6):1125-1130. PMID: 32217937.
      Citations: 16     Fields:    Translation:Humans
    73. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002. PMID: 31895709.
      Citations: 8     Fields:    Translation:Humans
    74. Cao J, Hu J, Liu S, Meric-Bernstam F, Abdel-Wahab R, Xu J, Li Q, Yan M, Feng Y, Lin J, Zhao S, Wang J, Kwong LN, Hu J, Carapeto F, Borad MJ, Wang K, Javle M, Zhao H. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis Oncol. 2020; 4. PMID: 32923885; PMCID: PMC7446410.
      Citations: 14     Fields:    
    75. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807. PMID: 32416072; PMCID: PMC7523268.
      Citations: 157     Fields:    Translation:HumansCTClinical Trials
    76. Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka K. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773. PMID: 32377978; PMCID: PMC7575509.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    77. Kim RD, McDonough S, El-Khoueiry AB, Bekaii-Saab TS, Stein SM, Sahai V, Keogh GP, Kim EJ, Baron AD, Siegel AB, Barzi A, Guthrie KA, Javle M, Hochster H. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Eur J Cancer. 2020 05; 130:219-227. PMID: 32234665; PMCID: PMC7539324.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    78. Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev. 2020 Jun; 86:101998. PMID: 32203843; PMCID: PMC8222858.
      Citations: 8     Fields:    Translation:HumansAnimals
    79. Javle M. On the cusp of a sea change in biliary tract cancer. Chin Clin Oncol. 2020 Feb; 9(1):1. PMID: 32075398.
      Citations:    Fields:    Translation:Humans
    80. Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. J Gastrointest Oncol. 2020 Feb; 11(1):55-60. PMID: 32175105; PMCID: PMC7052763.
      Citations: 1     
    81. Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020 02; 8(1). PMID: 32114502; PMCID: PMC7057435.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    82. Mosconi C, Calandri M, Javle M, Odisio BC. Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chin Clin Oncol. 2020 Feb; 9(1):8. PMID: 32008330.
      Citations: 2     Fields:    Translation:Humans
    83. Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504. PMID: 31932214; PMCID: PMC7160008.
      Citations: 7     Fields:    Translation:Humans
    84. Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle MM, Shroff RT, Varadhachary GR, Wolff RA, McAllister F, Futreal A, Fogelman DR. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394. PMID: 31871297.
      Citations: 14     Fields:    Translation:Humans
    85. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931. PMID: 31852833; PMCID: PMC7771658.
      Citations: 17     Fields:    Translation:Humans
    86. Yang P, Javle M, Pang F, Zhao W, Abdel-Wahab R, Chen X, Meric-Bernstam F, Chen H, Borad MJ, Liu Y, Zou C, Mu S, Xing Y, Wang K, Peng C, Che X. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 2019 Dec; 8(6):604-614. PMID: 31929987; PMCID: PMC6943012.
      Citations: 18     
    87. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3. PMID: 32923865; PMCID: PMC7446516.
      Citations: 4     Fields:    
    88. Kahle MP, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Javle M, Kaseb A, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Mills Shaw KR, Meric-Bernstam F, S?nchez NS. Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precis Oncol. 2019; 3. PMID: 32923868; PMCID: PMC7448805.
      Citations: 3     Fields:    
    89. Koay EJ, Katz MHG, Wang H, Wang X, Prakash L, Javle M, Shroff R, Fogelman D, Avila S, Zaid M, Elganainy D, Lee Y, Crane CH, Krishnan S, Das P, Fleming JB, Lee JE, Tamm EP, Bhosale P, Lee JH, Weston B, Maitra A, Wolff RA, Varadhachary GR. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol. 2019; 3. PMID: 32914036; PMCID: PMC7446521.
      Citations: 6     Fields:    
    90. Javle M, Zhao H, Abou-Alfa GK. Systemic therapy for gallbladder cancer. Chin Clin Oncol. 2019 08; 8(4):44. PMID: 31484490; PMCID: PMC8219347.
      Citations: 8     Fields:    Translation:Humans
    91. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):824-830. PMID: 30998813; PMCID: PMC6567834.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    92. Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61. PMID: 30935582; PMCID: PMC6446916.
      Citations: 17     Fields:    Translation:Humans
    93. Odisio BC, Krampitz GW, Murthy R, Mahvash A, Javle M, Vauthey JN. Preoperative drainage for perihilar cholangiocarcinoma. Lancet Gastroenterol Hepatol. 2019 01; 4(1):10-11. PMID: 30527574.
      Citations: 1     Fields:    Translation:Humans
    94. Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, Javle M, Glenjen NI, Abelseth BK, Gilje B, Nordg?rd O. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018 11 06; 16(1):300. PMID: 30400802; PMCID: PMC6218961.
      Citations: 34     Fields:    Translation:Humans
    95. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. PMID: 30383888; PMCID: PMC6340722.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    96. Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-Shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab T, Shroff RT, Javle M. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol. 2018 Nov; 2:1-12. PMID: 35135097.
      Citations: 8     Fields:    
    97. Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627. PMID: 30324485.
      Citations: 5     Fields:    Translation:Humans
    98. Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. 2018 10 01; 124(19):3890-3899. PMID: 30299542.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    99. Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019 01; 156(1):108-118.e4. PMID: 30240661; PMCID: PMC6434712.
      Citations: 114     Fields:    Translation:HumansCells
    100. Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892. PMID: 30152073; PMCID: PMC6198206.
      Citations: 9     Fields:    Translation:Humans
    101. Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, Tanwar P, Khan A, Javle M, Hassan MM, Pant S, De Aretxabala X, Sirohi B, Rajaraman P, Kaur T, Rath GK. Genetic landscape of gallbladder cancer: Global overview. Mutat Res Rev Mutat Res. 2018 Oct - Dec; 778:61-71. PMID: 30454684.
      Citations: 20     Fields:    Translation:Humans
    102. Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2018 12 01; 24(23):5883-5894. PMID: 30082477; PMCID: PMC6279613.
      Citations: 31     Fields:    Translation:HumansCells
    103. Lunsford KE, Javle M, Gaber AO, Vauthey JN, Ghobrial RM. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma - Authors' reply. Lancet Gastroenterol Hepatol. 2018 08; 3(8):529-530. PMID: 30047444.
      Citations: 3     Fields:    Translation:Humans
    104. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291. PMID: 29668571; PMCID: PMC6028046.
      Citations: 3     Fields:    Translation:Humans
    105. Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71. PMID: 29843755; PMCID: PMC5975422.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    106. Finn RS, Ahn DH, Javle MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018 12; 36(6):1037-1043. PMID: 29785570.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    107. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601. PMID: 29654067; PMCID: PMC6310221.
      Citations: 11     Fields:    Translation:HumansCells
    108. Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell. 2018 04 09; 33(4):752-769.e8. PMID: 29606349; PMCID: PMC5893359.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    109. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM, Methodist?MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC). Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018 05; 3(5):337-348. PMID: 29548617.
      Citations: 47     Fields:    Translation:Humans
    110. Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol. 2018 01 01; 29(1):223-229. PMID: 29045505; PMCID: PMC6248757.
      Citations: 70     Fields:    Translation:HumansCells
    111. Sheth RA, Sabir SH, Parmet P, Amin R, Kuban JD, Huang SY, Mahvash A, Fogelman D, Javle M, Wallace MJ. Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension. Oncologist. 2018 06; 23(6):712-718. PMID: 29284759; PMCID: PMC6067944.
      Citations: 3     Fields:    Translation:Humans
    112. Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. 2018 03; 23(3):277-e26. PMID: 29259073; PMCID: PMC5905687.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    113. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282. PMID: 29182496; PMCID: PMC6075847.
      Citations: 187     Fields:    Translation:HumansCTClinical Trials
    114. Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056. PMID: 28700784; PMCID: PMC5710421.
      Citations: 26     Fields:    Translation:Humans
    115. Sakellariou-Thompson D, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C, Forget MA. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res. 2017 Dec 01; 23(23):7263-7275. PMID: 28947567; PMCID: PMC6097625.
      Citations: 21     Fields:    Translation:HumansCells
    116. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173. PMID: 29152071; PMCID: PMC5675623.
      Citations:    Fields:    
    117. Golan T, Javle M. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. J Natl Compr Canc Netw. 2017 08; 15(8):1063-1069. PMID: 28784866.
      Citations: 11     Fields:    Translation:HumansCells
    118. Chun YS, Javle M. Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control. 2017 Jul-Sep; 24(3):1073274817729241. PMID: 28975832; PMCID: PMC5937242.
      Citations: 50     Fields:    Translation:Humans
    119. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799. PMID: 28579181; PMCID: PMC5901750.
      Citations: 33     Fields:    Translation:Humans
    120. Lapin M, Tjensvoll K, Oltedal S, Javle M, Smaaland R, Gilje B, Nordg?rd O. Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. BMC Cancer. 2017 05 31; 17(1):390. PMID: 28569190; PMCID: PMC5452374.
      Citations: 22     Fields:    Translation:HumansCells
    121. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656. PMID: 28536309; PMCID: PMC5600825.
      Citations: 27     Fields:    Translation:Humans
    122. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 07; 22(7):804-810. PMID: 28487467; PMCID: PMC5507643.
      Citations: 35     Fields:    Translation:Humans
    123. Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr. 2017 Apr; 6(2):105-116. PMID: 28503558; PMCID: PMC5411273.
      Citations: 15     
    124. Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer. 2017 Mar 14; 116(6):697-702. PMID: 28183138; PMCID: PMC5355924.
      Citations: 28     Fields:    Translation:Humans
    125. Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28; 116(5):575-583. PMID: 28152546; PMCID: PMC5344293.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    126. Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039. PMID: 28124275.
      Citations: 8     Fields:    Translation:Humans
    127. Yamashita S, Passot G, Aloia TA, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg. 2017 Feb; 104(3):267-277. PMID: 28052308.
      Citations: 19     Fields:    Translation:Humans
    128. Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, Chun YS, Aloia TA, Tao R, Kaseb A, Javle M, Crane CH, Vauthey JN. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer. 2017 04 15; 123(8):1354-1362. PMID: 27984655; PMCID: PMC5384875.
      Citations: 17     Fields:    Translation:Humans
    129. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827. PMID: 28078106; PMCID: PMC5177567.
      Citations: 9     
    130. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer. 2017 May 15; 123(6):1011-1017. PMID: 27859010; PMCID: PMC5548379.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    131. Chadha AS, Liu G, Chen HC, Das P, Minsky BD, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH, Wang X, Thames H, Krishnan S. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):323-332. PMID: 28068240.
      Citations: 37     Fields:    Translation:Humans
    132. Jain A, Kwong LN, Javle M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol. 2016 11; 17(11):58. PMID: 27658789.
      Citations: 41     Fields:    Translation:HumansCells
    133. Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174. PMID: 27778257.
      Citations: 38     Fields:    Translation:Humans
    134. Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985. PMID: 27730398.
      Citations: 7     Fields:    Translation:Humans
    135. Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol. 2016 Oct; 7(5):797-803. PMID: 27747093; PMCID: PMC5056250.
      Citations: 27     
    136. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122(24):3838-3847. PMID: 27622582.
      Citations: 108     Fields:    Translation:HumansCells
    137. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 12 01; 122(23):3657-3666. PMID: 27495988; PMCID: PMC5222890.
      Citations: 21     Fields:    Translation:Humans
    138. Al-Shamsi HO, Anand D, Shroff RT, Jain A, Zuo M, Conrad C, Vauthey JN, Javle MM. BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. J Gastrointest Oncol. 2016 Aug; 7(4):556-61. PMID: 27563445; PMCID: PMC4963380.
      Citations: 9     
    139. Yamashita S, Loyer E, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C. Laparoscopic Management of Gallbladder Cancer: A Stepwise Approach. Ann Surg Oncol. 2016 12; 23(Suppl 5):892-893. PMID: 27456958.
      Citations: 2     Fields:    Translation:Humans
    140. Chadha AS, Skinner HD, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910. PMID: 27336466; PMCID: PMC4919049.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    141. Zuo M, Rashid A, Wang Y, Jain A, Li D, Behari A, Kapoor VK, Koay EJ, Chang P, Vauthey JN, Li Y, Espinoza JA, Javle M, Roa JC. RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer. Oncotarget. 2016 Jun 07; 7(23):35302-12. PMID: 27167107; PMCID: PMC5085230.
      Citations: 5     Fields:    Translation:Humans
    142. Ismael HN, Denbo J, Cox S, Crane CH, Das P, Krishnan S, Schroff RT, Javle M, Conrad C, Vauthey J, Aloia T. Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. Eur J Surg Oncol. 2016 Oct; 42(10):1591-6. PMID: 27296729.
      Citations: 4     Fields:    Translation:Humans
    143. Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9. PMID: 27243381; PMCID: PMC4992463.
      Citations: 14     Fields:    Translation:Humans
    144. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 08 01; 34(22):2654-68. PMID: 27247216.
      Citations: 114     Fields:    Translation:Humans
    145. Chen J, Raju GS, Jogunoori W, Menon V, Majumdar A, Chen JS, Gi YJ, Jeong YS, Phan L, Belkin M, Gu S, Kundra S, Mistry NA, Zhang J, Su X, Li S, Lin SH, Javle M, McMurray JS, Rahlfs TF, Mishra B, White J, Rashid A, Beauchemin N, Weston BR, Shafi MA, Stroehlein JR, Davila M, Akbani R, Weinstein JN, Wu X, Mishra L. Mutational Profiles Reveal an Aberrant TGF-?-CEA Regulated Pathway in Colon Adenomas. PLoS One. 2016; 11(4):e0153933. PMID: 27100181; PMCID: PMC4839765.
      Citations: 10     Fields:    Translation:HumansCells
    146. Espinoza JA, Javle M, Koshiol J, Bizama C, Garc?a P, Ferreccio C, Miquel JF, Roa JC. The inflammatory inception of gallbladder cancer. Biochim Biophys Acta. 2016 Apr; 1865(2):245-54. PMID: 26980625; PMCID: PMC6287912.
      Citations: 36     Fields:    Translation:Humans
    147. Roa I, Garcia H, Game A, de Toro G, Javle M, de Aretxabala X. Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Additional Options for an Orphan Cancer. J Mol Diagn. 2016 05; 18(3):388-394. PMID: 26947513.
      Citations: 6     Fields:    Translation:Humans
    148. Javle M, Golan T, Maitra A. Changing the course of pancreatic cancer--Focus on recent translational advances. Cancer Treat Rev. 2016 Mar; 44:17-25. PMID: 26924195.
      Citations: 13     Fields:    Translation:HumansCells
    149. Chen J, Yao ZX, Chen JS, Gi YJ, Kundra S, Herlong HF, Jeong YS, Goltsov A, Ohshiro K, Mistry NA, Zhang J, Su X, Choufani S, Mitra A, Li S, Mishra B, White J, Rashid A, Wang AY, Javle M, Davila M, Michaely P, Weksberg R, Hofstetter WL, Finegold MJ, Shay JW, Machida K, Tsukamoto H, Mishra L, Mu?oz NM. TGF-?/?2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest. 2016 Feb; 126(2):527-42. PMID: 26784546; PMCID: PMC4731168.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    150. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8. PMID: 26668346; PMCID: PMC4872014.
      Citations: 149     Fields:    Translation:HumansCTClinical Trials
    151. Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):755-65. PMID: 26972648; PMCID: PMC4792191.
      Citations: 119     Fields:    Translation:Humans
    152. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20; 34(3):219-26. PMID: 26503201; PMCID: PMC4980564.
      Citations: 77     Fields:    Translation:Humans
    153. Lee H, Wang K, Johnson A, Jones DM, Ali SM, Elvin JA, Yelensky R, Lipson D, Miller VA, Stephens PJ, Javle M, Ross JS. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol. 2016 May; 69(5):403-8. PMID: 26500333.
      Citations: 24     Fields:    Translation:Humans
    154. Roland CL, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8. PMID: 26350371; PMCID: PMC5192562.
      Citations: 19     Fields:    Translation:Humans
    155. Game A, Javle M, Roa I, de Toro G, Fern?ndez F, Mu?oz S, de Aretxabala X. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagn Pathol. 2015 Aug 21; 10:148. PMID: 26294099; PMCID: PMC4546176.
      Citations: 10     Fields:    Translation:Humans
    156. Aloia TA, Javle M, Maithel SK, Roa JC, Adsay V, Jarnagin WR, J?rufe N, Coimbra FJ. Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015 Aug; 17(8):681-90. PMID: 26172135; PMCID: PMC4527853.
      Citations: 102     Fields:    Translation:Humans
    157. Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA, Abbruzzese JL, Laheru D, Diaz LA. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015 Sep; 76(3):489-498. PMID: 26126726; PMCID: PMC4811030.
      Citations: 31     Fields:    Translation:Humans
    158. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015 May 29; 8:58. PMID: 26022204; PMCID: PMC4469402.
      Citations: 77     Fields:    Translation:Humans
    159. Zuo M, Li C, Lin J, Javle M. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Oncotarget. 2015 May 10; 6(13):10940-9. PMID: 25883212; PMCID: PMC4484430.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    160. de Aretxabala X, Aloia TA, Roa JC, Roa I, Zimmitti G, Javle M, Conrad C, Maru DM, Aoki T, Vigano L, Ribero D, Kokudo N, Capussotti L, Vauthey JN, Shindoh J. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015 Apr; 261(4):733-9. PMID: 24854451; PMCID: PMC4800978.
      Citations: 59     Fields:    Translation:Humans
    161. Zuo M, Rashid A, Churi C, Vauthey JN, Chang P, Li Y, Hung MC, Li D, Javle M. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. Br J Cancer. 2015 Mar 17; 112(6):1042-51. PMID: 25742482; PMCID: PMC4366884.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    162. Chadha AS, Kocak-Uzel E, Das P, Minsky BD, Delclos ME, Mahmood U, Guha S, Ahmad M, Varadhachary GR, Javle M, Katz MH, Fleming JB, Wolff RA, Crane CH, Krishnan S. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015 Jul; 54(7):971-8. PMID: 25608822.
      Citations: 28     Fields:    Translation:Humans
    163. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383. PMID: 25536104; PMCID: PMC4275227.
      Citations: 170     Fields:    Translation:HumansCells
    164. Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014 Dec; 5(6):408-13. PMID: 25436118; PMCID: PMC4226829.
      Citations: 20     
    165. Anwar S, Tan W, Yu J, Hutson A, Javle M, Iyer R. Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial. J Gastrointest Oncol. 2014 Dec; 5(6):433-9. PMID: 25436122; PMCID: PMC4226818.
      Citations: 8     
    166. Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002. PMID: 25427073; PMCID: PMC4266401.
      Citations: 20     Fields:    Translation:Humans
    167. Javle M, Smyth EC, Chau I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res. 2014 Dec 01; 20(23):5875-81. PMID: 25281695; PMCID: PMC4252869.
      Citations: 28     Fields:    Translation:Humans
    168. Mukherjee S, Javle M, Huguet F. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Clin Oncol (R Coll Radiol). 2014 Sep; 26(9):560-8. PMID: 25001636.
      Citations: 22     Fields:    Translation:Humans
    169. Liu C, Karam R, Zhou Y, Su F, Ji Y, Li G, Xu G, Lu L, Wang C, Song M, Zhu J, Wang Y, Zhao Y, Foo WC, Zuo M, Valasek MA, Javle M, Wilkinson MF, Lu Y. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat Med. 2014 Jun; 20(6):596-8. PMID: 24859531; PMCID: PMC4048332.
      Citations: 65     Fields:    Translation:HumansCells
    170. Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, Garg N, Varadhachary GR, Shroff R, Overman MJ, Garrett C, Wolff RA, Javle M. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014 Dec; 5(4):307-13. PMID: 24740741; PMCID: PMC4248412.
      Citations: 11     Fields:    
    171. Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH, Van Loon K. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. PMID: 24622062; PMCID: PMC3955845.
      Citations: 5     Fields:    Translation:Humans
    172. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36. PMID: 24614108; PMCID: PMC3973100.
      Citations: 96     Fields:    Translation:HumansCTClinical Trials
    173. de Toro G, Schalper K, Churi C, Javle M, Roa I, de Aretxabala X. Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res. 2014 Mar; 7(2):42-8. PMID: 24799970; PMCID: PMC4007675.
      Citations: 37     
    174. Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, Li D. Biomarkers of TGF-? signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014; 9(1):e85942. PMID: 24465802; PMCID: PMC3896410.
      Citations: 52     Fields:    Translation:HumansCells
    175. Javle M, Rashid A, Churi C, Kar S, Zuo M, Eterovic AK, Nogueras-Gonzalez GM, Janku F, Shroff RT, Aloia TA, Vauthey JN, Curley S, Mills G, Roa I. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014 Apr; 45(4):701-8. PMID: 24508317; PMCID: PMC4428571.
      Citations: 34     Fields:    Translation:Humans
    176. Tanasanvimon S, Garg N, Viswanathan C, Truong M, Kaur H, Kee BK, Sahin IH, Javle MM, Garrett CR. High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study. Thromb Res. 2014 Feb; 133(2):154-7. PMID: 24331209.
      Citations: 3     Fields:    Translation:Humans
    177. Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83. PMID: 23645398.
      Citations: 4     Fields:    Translation:Humans
    178. Atiq M, Bhutani MS, Ross WA, Raju GS, Gong Y, Tamm EP, Javle M, Wang X, Lee JH. Role of endoscopic ultrasonography in evaluation of metastatic lesions to the pancreas: a tertiary cancer center experience. Pancreas. 2013 Apr; 42(3):516-23. PMID: 23211369.
      Citations: 14     Fields:    Translation:Humans
    179. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555; PMCID: PMC3702215.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    180. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):344-8. PMID: 24674408.
      Citations: 2     Fields:    
    181. Kunkeaw N, Jeon SH, Lee K, Johnson BH, Tanasanvimon S, Javle M, Pairojkul C, Chamgramol Y, Wongfieng W, Gong B, Leelayuwat C, Lee YS. Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene. 2013 Aug 08; 32(32):3722-31. PMID: 22926522; PMCID: PMC3869796.
      Citations: 43     Fields:    Translation:HumansCells
    182. Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012 Feb; 75(2):332-8. PMID: 22248601; PMCID: PMC4380192.
      Citations: 46     Fields:    Translation:HumansCellsCTClinical Trials
    183. Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol. 2011 Nov; 3(6):257-67. PMID: 22084640; PMCID: PMC3210467.
      Citations: 33     
    184. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011 Oct 11; 105(8):1114-22. PMID: 21989215; PMCID: PMC3208503.
      Citations: 113     Fields:    Translation:HumansCells
    185. Eckmann KR, Patel DK, Landgraf A, Slade JH, Lin E, Kaur H, Loyer E, Weatherly JM, Javle M. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res. 2011 Sep; 4(5-6):155-60. PMID: 22295126; PMCID: PMC3269144.
      Citations: 26     
    186. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol. 2011 Nov; 50(8):1191-8. PMID: 21793641.
      Citations: 11     Fields:    Translation:Humans
    187. Singal AK, Ross WA, Guturu P, Varadhachary GR, Javle M, Jaganmohan SR, Raju RP, Fleming JB, Raju GS, Kuo YF, Lee JH. Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases. Dig Dis Sci. 2011 Dec; 56(12):3678-84. PMID: 21750930.
      Citations: 13     Fields:    Translation:Humans
    188. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43. PMID: 21709185; PMCID: PMC3157965.
      Citations: 109     Fields:    Translation:HumansCTClinical Trials
    189. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Ann Surg Oncol. 2011 Dec; 18(13):3615-22. PMID: 21701927.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    190. Golan T, Javle M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology (Williston Park). 2011 May; 25(6):518-26, 529. PMID: 21717907.
      Citations: 13     Fields:    Translation:HumansCells
    191. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 2011 Apr; 31(4):1417-20. PMID: 21508395.
      Citations: 43     Fields:    Translation:Humans
    192. Raju RP, Jaganmohan SR, Ross WA, Davila ML, Javle M, Raju GS, Lee JH. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci. 2011 May; 56(5):1557-64. PMID: 21222156.
      Citations: 33     Fields:    Translation:Humans
    193. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15; 116(22):5325-35. PMID: 20665488; PMCID: PMC2966859.
      Citations: 34     Fields:    Translation:Humans
    194. Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med. 2010 Nov 02; 2:147-55. PMID: 24367212; PMCID: PMC3846497.
      Citations: 3     
    195. Atiq M, Javle M, Dang S, Lee JH. Cholangiocarcinoma: an endoscopist's perspective. Expert Rev Gastroenterol Hepatol. 2010 Oct; 4(5):601-11. PMID: 20932145.
      Citations:    Fields:    Translation:Humans
    196. Huang TC, Kar S, Javle M. Personalized therapy for pancreatic cancer: Myth or reality in 2010? J Gastrointest Oncol. 2010 Sep; 1(1):24-33. PMID: 22811802; PMCID: PMC3397566.
      Citations: 4     
    197. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14; 10:368. PMID: 20630061; PMCID: PMC2910694.
      Citations: 81     Fields:    Translation:HumansCellsCTClinical Trials
    198. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3. PMID: 20416304; PMCID: PMC2910789.
      Citations: 29     Fields:    Translation:HumansCells
    199. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010 Apr 15; 116(8):1938-46. PMID: 20166205; PMCID: PMC4123320.
      Citations: 117     Fields:    Translation:Humans
    200. Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2010; 78(2):125-9. PMID: 20389134.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    201. Javle M, Hsueh CT. Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol. 2010 Mar 23; 3:11. PMID: 20331897; PMCID: PMC2856525.
      Citations: 19     Fields:    Translation:Humans
    202. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9. PMID: 20107864.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    203. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res. 2010 Jan 01; 16(1):320-9. PMID: 20028759; PMCID: PMC2802655.
      Citations: 43     Fields:    Translation:Humans
    204. Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR, Wolff RA, Das P. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol. 2009 Nov 18; 4:55. PMID: 19922641; PMCID: PMC2787526.
      Citations: 8     Fields:    Translation:Humans
    205. Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009 Oct; 29(10):4127-30. PMID: 19846960.
      Citations: 15     Fields:    Translation:Humans
    206. Chadha MK, Litwin A, Levea C, Iyer R, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. JOP. 2009 Sep 04; 10(5):535-8. PMID: 19734632.
      Citations: 4     Fields:    Translation:HumansCells
    207. May KS, Khushalani NI, Chandrasekhar R, Wilding GE, Iyer RV, Ma WW, Flaherty L, Russo RC, Fakih M, Kuvshinoff BW, Gibbs JF, Javle MM, Yang GY. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1193-8. PMID: 19540051.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    208. Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer. 2009 Jun 16; 100(12):1842-5. PMID: 19491904; PMCID: PMC2714236.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    209. Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol. 2009 Feb 23; 2:9. PMID: 19236713; PMCID: PMC2654905.
      Citations: 12     Fields:    Translation:Humans
    210. Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest. 2009 Feb; 27(2):193-200. PMID: 19235592.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    211. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw. 2008 Nov; 6(10):1026-60. PMID: 19176200.
      Citations:    Fields:    Translation:Humans
    212. Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, Dowlati A, Kantharaj BN, Schluchter MD, Rath L, Ivy SP, Remick SC. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol. 2009 Apr; 63(5):851-7. PMID: 18670776; PMCID: PMC4209292.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    213. Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol. 2008 Aug; 31(4):329-34. PMID: 18845990.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    214. Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea CM, Javle MM. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology. 2007; 73(5-6):281-9. PMID: 18477853.
      Citations: 15     Fields:    Translation:Humans
    215. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D, Khoury T. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007 Dec; 14(12):3527-33. PMID: 17879119.
      Citations: 83     Fields:    Translation:HumansCells
    216. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol. 2007 Sep; 5(8):355-63. PMID: 17944143.
      Citations: 12     Fields:    Translation:Humans
    217. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007 Sep-Oct; 27(5B):3465-70. PMID: 17972502.
      Citations: 33     Fields:    Translation:Humans
    218. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol. 2007 Nov; 14(11):3202-9. PMID: 17705089.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    219. Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A, Lin E. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007 Aug; 30(4):350-7. PMID: 17762434.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    220. Ailawadhi S, Nagase H, Khoury T, Yu J, Tan D, Black J, Brattain M, Javle M. Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology. 2007 Jul-Aug; 54(77):1339-44. PMID: 17708250.
      Citations: 3     Fields:    Translation:Humans
    221. Javle M, Yang GY. Review: neoadjuvant chemoradiotherapy and chemotherapy improve survival in operable esophageal cancer. ACP J Club. 2007 Jul-Aug; 147(1):19. PMID: 17608384.
      Citations:    Fields:    
    222. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 01; 13(7):2091-9. PMID: 17404091.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    223. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg. 2007 Apr; 11(4):445-51. PMID: 17436128; PMCID: PMC1852393.
      Citations: 13     Fields:    Translation:Humans
    224. Javle M, Shah P, Yu J, Bhagat V, Litwin A, Iyer R, Gibbs J. Cystic pancreatic tumors (CPT): predictors of malignant behavior. J Surg Oncol. 2007 Mar 01; 95(3):221-8. PMID: 17323335.
      Citations: 4     Fields:    Translation:Humans
    225. O'Connor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J. 2007 Mar-Apr; 13(2):119-24. PMID: 17476140.
      Citations: 9     Fields:    Translation:Humans
    226. Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF, Creaven PJ, Noel DC, Iyer RV, Rustum YM. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res. 2007 Feb 01; 13(3):965-71. PMID: 17289892.
      Citations: 12     Fields:    Translation:HumansAnimalsCTClinical Trials
    227. Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol. 2007 Feb; 14(2):752-8. PMID: 17146741.
      Citations: 6     Fields:    Translation:HumansCells
    228. Foster JM, Hoshi H, Gibbs JF, Iyer R, Javle M, Chu Q, Kuvshinoff B. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol. 2007 Feb; 14(2):833-40. PMID: 17103074.
      Citations: 66     Fields:    Translation:Humans
    229. Javle MM, Yu J, Khoury T, Chadha KS, Chadha KC, Iyer RV, Foster J, Kuvshinoff BW, Gibbs JF, Geradts J, Black JD, Brattain MG. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol. 2006 Nov; 21(11):1744-51. PMID: 16984600.
      Citations: 23     Fields:    Translation:HumansCells
    230. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007 Apr; 59(5):581-7. PMID: 17066293.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    231. Leichman L, Lawrence D, Leichman CG, Nava H, Nava E, Proulx G, Clark K, Khushalani NI, Berdzik J, Greco W, Smith P, Creaven PJ, Kepner JL, Javle MM, Pendyala L. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J Chemother. 2006 Oct; 18(5):514-24. PMID: 17127229.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    232. Javle M, Ailawadhi S, Yang GY, Nwogu CE, Schiff MD, Nava HR. Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol. 2006 Sep; 4(8):365-73, 379. PMID: 17004508.
      Citations: 30     Fields:    Translation:Humans
    233. Jayaprakash V, Menezes RJ, Javle MM, McCann SE, Baker JA, Reid ME, Natarajan N, Moysich KB. Regular aspirin use and esophageal cancer risk. Int J Cancer. 2006 Jul 01; 119(1):202-7. PMID: 16450404.
      Citations: 10     Fields:    Translation:Humans
    234. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006 Jul; 13(7):933-9. PMID: 16788754.
      Citations: 52     Fields:    Translation:HumansCells
    235. Bdair FM, Graham SP, Smith PF, Javle MM. Gemcitabine and acute myocardial infarction--a case report. Angiology. 2006 May-Jun; 57(3):367-71. PMID: 16703198.
      Citations: 5     Fields:    Translation:Humans
    236. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):328-47. PMID: 16569387.
      Citations: 5     Fields:    Translation:Humans
    237. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):350-66. PMID: 16569388.
      Citations: 11     Fields:    Translation:Humans
    238. Bhagat V, Javle M, Yu J, Agrawal A, Gibbs JF, Kuvshinoff B, Nava E, Iyer R. Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer. 2006; 37(1):27-34. PMID: 17290078.
      Citations: 9     Fields:    Translation:Humans
    239. Javle MM, Nwogu CE, Donohue KA, Iyer RV, Brady WE, Khemka SV, Smith JL, Demmy TL, Yang GY, Nava HR. Management of locoregional stage esophageal cancer: a single center experience. Dis Esophagus. 2006; 19(2):78-83. PMID: 16643174.
      Citations: 3     Fields:    Translation:Humans
    240. Chadha KS, Hernandez-Ilizaliturri FJ, Javle M. Primary esophageal lymphoma: case series and review of the literature. Dig Dis Sci. 2006 Jan; 51(1):77-83. PMID: 16416216.
      Citations: 8     Fields:    Translation:Humans
    241. Sikander A, Sadashiv S, Ronald S, Milind J. Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: a case report and review of the literature. Am J Clin Oncol. 2005 Dec; 28(6):638-9. PMID: 16317281.
      Citations: 1     Fields:    Translation:Humans
    242. Watwe V, Javle M, Lawrence D, Groth J, Iyer R, El-Hajjar D, Geradts J. Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. Am J Clin Oncol. 2005 Dec; 28(6):560-4. PMID: 16317264.
      Citations: 5     Fields:    Translation:Humans
    243. Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005 Nov 01; 11(21):7794-9. PMID: 16278401.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    244. Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clin Cancer Res. 2005 Aug 15; 11(16):5942-9. PMID: 16115937.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    245. Bahadur S, Shaukat A, Gibbs J, Litwin A, Nava H, Melnyk M, Javle M. Cisplatin and gemcitabine for small cell carcinoma of the gall bladder. Am J Clin Oncol. 2005 Aug; 28(4):425-6. PMID: 16062088.
      Citations: 6     Fields:    Translation:Humans
    246. Chadha MK, Kuvshinoff BW, Javle MM. Neoadjuvant therapy for gastric cancer. Oncology (Williston Park). 2005 Aug; 19(9):1219-27; discussion 1227-8, 1231-2. PMID: 16255136.
      Citations: 3     Fields:    Translation:Humans
    247. Nallapareddy S, Wilding GE, Yang G, Iyer R, Javle M. Chemoradiation is a tolerable therapy for older adults with esophageal cancer. Anticancer Res. 2005 Jul-Aug; 25(4):3055-60. PMID: 16080565.
      Citations: 10     Fields:    Translation:Humans
    248. Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, Pendyala L, Smith PF, Stewart CC, Hoffman JL, Javle MM, Berdzik J, Creaven PJ, Rustum YM. S-phase modulation by irinotecan: pilot studies in advanced solid tumors. Cancer Chemother Pharmacol. 2005 Nov; 56(5):447-54. PMID: 15947933.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    249. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer. 2005 Apr 20; 114(4):509-12. PMID: 15578717; PMCID: PMC2829944.
      Citations: 78     Fields:    Translation:HumansCells
    250. Ettinger DS, Arnoletti JP, Gockerman JP, Handorf C, Havlin KA, Jacobs CD, Javle M, Kvols L, Lenzi R, Rashid A, Rhoades CA, Ridge JA, Saltz L, Shulman LN, Sondak VK, Thompson JA, Twardowski P, Zhen W, National Comprehensive Cancer Network. Occult primary cancer clinical practice guidelines. J Natl Compr Canc Netw. 2005 Mar; 3(2):214-33. PMID: 19817031.
      Citations: 2     Fields:    Translation:Humans
    251. Mortazavi A, Shaukat A, Othman E, Kepner JL, Fakih MG, Kuvshinoff BW, Smith JL, Javle MM. Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study? Am J Clin Oncol. 2005 Feb; 28(1):30-5. PMID: 15685032.
      Citations: 4     Fields:    Translation:Humans
    252. Khoury T, Chadha K, Javle M, Donohue K, Levea C, Iyer R, Okada H, Nagase H, Tan D. Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer. 2005; 35(3):171-7. PMID: 16110118.
      Citations: 17     Fields:    Translation:Humans
    253. Tripp P, Malhotra HK, Javle M, Shaukat A, Russo R, De Boer S, Podgorsak M, Nava H, Yang GY. Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Dis Esophagus. 2005; 18(6):400-5. PMID: 16336612.
      Citations: 10     Fields:    Translation:Humans
    254. James TA, Sheldon DG, Rajput A, Kuvshinoff BW, Javle MM, Nava HR, Smith JL, Gibbs JF. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer. 2004 Dec 15; 101(12):2722-6. PMID: 15534880.
      Citations: 32     Fields:    Translation:Humans
    255. Chadha MK, LeVea C, Javle M, Kuvshinoff B, Vijaykumar R, Iyer R. Anaplastic pancreatic carcinoma. A case report and review of literature . JOP. 2004 Nov 10; 5(6):512-5. PMID: 15536293.
      Citations: 7     Fields:    Translation:Humans
    256. Gowda A, Goel R, Berdzik J, Leichman CG, Javle M. Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park). 2004 Nov; 18(13):1671-5; discussion 1676, 1680, 1683-4. PMID: 15648298.
      Citations: 19     Fields:    Translation:Humans
    257. Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, Gibbs JF. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology. 2004 Nov-Dec; 51(60):1653-7. PMID: 15532797.
      Citations: 12     Fields:    Translation:Humans
    258. Palesty JA, Wang W, Javle MM, Yang GY. Side effects of therapy: case 3. Gastric cancer after radiotherapy of pediatric Hodgkin's disease. J Clin Oncol. 2004 Jun 15; 22(12):2507-9. PMID: 15197215.
      Citations: 2     Fields:    Translation:Humans
    259. Iyer R, Wilkinson N, Demmy T, Javle M. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol. 2004 Jul; 11(7):665-73. PMID: 15197012.
      Citations: 14     Fields:    Translation:Humans
    260. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004 May-Jun; 8(4):448-53. PMID: 15120370.
      Citations: 36     Fields:    Translation:Humans
    261. Shaukat A, Mortazavi A, Demmy T, Nava H, Wilkinson N, Yang G, Kepner J, Javle M. Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients? Dis Esophagus. 2004; 17(2):129-35. PMID: 15230725.
      Citations: 1     Fields:    Translation:Humans
    262. Varma GN, Winston JS, Hill HC, Gibbs JF, Proulx GM, McGrath BE, Javle MM. Unusual locations of involvement by malignancies: Case 3. Gastric signet ring carcinoma presenting as a diffuse thigh mass. J Clin Oncol. 2003 Sep 01; 21(17):3371-3. PMID: 12947076.
      Citations: 2     Fields:    Translation:Humans
    263. Chu QD, Khushalani N, Javle MM, Douglass HO, Gibbs JF. Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas? Ann Surg Oncol. 2003 Jun; 10(5):539-45. PMID: 12794020.
      Citations: 8     Fields:    Translation:Humans
    264. Bhagat V, Javle M, Geradts J. Carcinoma of the esophagus with mixed basaloid squamous and glandular differentiation: a distinct histological presentation. Int J Gastrointest Cancer. 2003; 34(2-3):139-42. PMID: 15361648.
      Citations:    Fields:    Translation:Humans
    265. Javle M, Raghavan D. Radiotherapy and chemotherapy for invasive bladder cancer. Cancer Surv. 1998; 31:149-60. PMID: 15281322.
      Citations:    Fields:    Translation:Humans
    266. Raghavan D, Koczwara B, Javle M. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer. 1997 Apr; 33(4):566-74. PMID: 9274436.
      Citations: 17     Fields:    Translation:Humans
    267. Javle M, Raghavan D. Total androgen blockade for prostate cancer: the end does not justify the means. Cancer Treat Res. 1996; 88:201-10. PMID: 9239481.
      Citations:    Fields:    Translation:Humans
    268. Javle M, Mangat G, Balakrishnan C, Joshi VR. Upper esophageal spasm in systemic sclerosis. J Assoc Physicians India. 1993 Aug; 41(8):545-6. PMID: 8294373.
      Citations:    Fields:    Translation:Humans
    269. Mutation profiling in cholangiocarcinoma. PLoS One. 9.
    270. Cholangiocarcinoma. 121-151.
    271. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 34:460-468.
    272. Laparoscopic Management of Gallbladder Cancer. Annals of Surgical Oncology. 1-2.
    273. Second-line systemic treatment for advanced cholangiocarcinoma. Journal of Gastrointestinal Oncology. 5:408-413.
    274. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Molecular Oncology.
    275. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Oncotarget. 6:10940-10949.
    276. Biliary cancer. Cancer.
    277. RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer. Oncotarget. 7:35302-35312.
    278. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery. 1-11.
    279. Chemotherapy for Cancer Pain Management. 459-464.
    280. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. British Journal of Surgery.
    281. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. Journal of Cachexia, Sarcopenia and Muscle. 5:307-313.
    282. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 34:219-226.
    283. Targets by organ site.
    284. Personalized medicine and targeted therapy of pancreatic cancer. 780-789.
    285. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater. Cancer.
    286. Cystic pancreatic lesions. 173-191.
    287. HER2/neu-directed therapy for biliary tract cancer. Journal of Hematology and Oncology. 8.
    288. Advances in cholangiocarcinoma research. Journal of Gastrointestinal Oncology. 7:819-827.
    289. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology.
    290. Phase i trial of consolidative radiotherapy with concurrent bevacizumab, erlotinib and capecitabine for unresectable pancreatic cancer. PLoS One. 11.
    291. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery. 1-11.
    292. Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer. Journal of Molecular Diagnostics. 18:388-394.
    293. Overexpression of the HER2/neu gene. Gastrointestinal Cancer Research. 7:42-48.
    294. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma. Gastrointestinal Cancer Research. 4:155-160.
    295. Progress in the treatment of invasive bladder cancer. Current Opinion in Urology. 6:280-285.
    296. Locally advanced, unresectable pancreatic cancer. Journal of Clinical Oncology. 34:2654-2667.
    297. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagnostic Pathology. 10.
    298. Gallbladder Cancer. HPB. 17:681-690.
    299. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Current Treatment Options in Oncology. 17.
    300. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Practical Radiation Oncology. 3:344-348.
    301. Erratum. American Journal of Clinical Oncology: Cancer Clinical Trials. 29:152.
    302. Systemic therapy for invasive bladder cancer. Cancer Control. 3:501-506.
    303. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?. International Journal of Radiation Oncology Biology Physics. 97:323-332.
    304. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology. 25.
    305. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. International Journal of Radiation Oncology Biology Physics. 94:755-765.
    306. Erratum. Journal of Gastroenterology and Hepatology (Australia). 22:145.
    307. TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. Journal of Clinical Investigation. 126:527-542.
    308. BRCA-associated protein 1 mutant cholangiocarcinoma. Journal of Gastrointestinal Oncology. 7:556-561.
    309. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 122:3657-3666.
    310. Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy. Journal of Gastrointestinal Oncology. 5:433-439.
    311. Mutational profiles reveal an aberrant TGF-β-CEA regulated pathway in colon adenomas. PLoS One. 11.
    312. Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy. European Journal of Surgical Oncology. 42:1591-1596.
    JAVLE's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (684)
    Explore
    _
    Co-Authors (184)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _